Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.68

-2.4%

Dec 12 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: schzammm who wrote (6119)	4/9/2002 9:02:39 PM
From: Miljenko Zuanic	of 52153

This sound as very good deal. <<Roche, which has exclusive worldwide marketing rights to the drug, will contribute about 70 per cent of the development cost and will also pay Isotechnika a percentage of gross profits.>> If percentage of the gross profit is 20% or better, than it is definitely good deal. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next